A report recently released by the Medicare Trustees projected that the life of the Medicare Trust Fund has been extended until 2023 – eight years longer than had been projected last year. This is a major change from 1993, when President Clinton received the trustees report projecting that Medicare would become insolvent in 1999.
A report recently released by the Medicare Trustees projected that the life of the Medicare Trust Fund has been extended until 2023 â eight years longer than had been projected last year. This is a major change from 1993, when President Clinton received the trustees report projecting that Medicare would become insolvent in 1999.
Despite the good news, however, the president pointed out that Medicare still faces daunting demographic and health challenges. The president also emphasized his comprehensive plan to make Medicare more competitive and efficient; modernize its benefits including adding a voluntary prescription drug benefit; and dedicating part of the budget surplus to meeting the future financial shortfall. Based on preliminary analysis, these policies are projected to extend the life of Medicare beyond 2030.
The report also revealed that Medicare premiums for a couple are $200 lower this year than they were estimated to be in the 1993 Trustees' projections. In 1993, the projected Part B premium for 2000 was $54.50. Today, it is actually $45.50 per month â a 17% decrease from the Trustees' 1993 projections. For an elderly couple, this is an annual savings of more than $200. PR
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.